Efficacy and Interaction of Antioxidant Supplements as Adjuvant Therapy in Cancer Treatment: A Systematic Review

Asuka Yasueda, BA¹, Hayato Urushima, PhD¹, and Toshinori Ito, PhD¹

Abstract
Oxidative stress is a key component in carcinogenesis. Although radiation produces reactive oxygen species, some anticancer agents such as alkylating agents, platinum and antitumor antibiotics exert cytotoxicity by generating free radicals. Nonenzymatic exogenous antioxidants such as vitamins, minerals, and polyphenols can quench ROS activity. However, whether antioxidants alter antitumor effects during radiotherapy and some types of chemotherapy remains unclear. In the present study, we reviewed antioxidants as an adjuvant therapy for cancer patients during chemotherapy or radiotherapy. Electronic literature searches were performed to select all randomized controlled clinical trials (RCTs) in which antioxidants were administered to cancer patients along with chemotherapy or radiotherapy. Articles or abstracts written in English were included. In total, 399 reports received primary screening. Duplicated articles and those meeting the exclusion criteria (not RCT, not human, and no oral administration) were excluded. Finally, 49 reports matching the inclusion criteria were included. It was difficult to determine whether antioxidants affect treatment outcomes or whether antioxidants ameliorate adverse effects induced by chemotherapy and radiotherapy. It is desirable to use an evidence-based method to select supplements best suited to cancer patients. Although there are many opinions about risks or benefits of antioxidant supplementation, we could mostly conclude that the harm caused by antioxidant supplementation remains unclear for patients during cancer therapy, except for smokers undergoing radiotherapy.

Keywords
cancer, antioxidant, chemotherapy, radiotherapy, supplement, vitamin

Introduction
Cancer is the leading cause of death worldwide. Although outcomes of cancer therapy have improved, cancer becomes a systemic disease beyond a particular point. Because complete recovery of cancer patients following a single treatment is quite difficult, a multidisciplinary approach combined with surgery, chemotherapy, radiotherapy, and immunotherapy is usually utilized.¹

Other approaches using complementary and alternative medicine (CAM) modalities are an important choice among cancer patients. Hyodo et al² reported that 44.6% of cancer patients use CAM treatments in Japan. Patients undergoing chemotherapy tend to prefer CAM, particularly dietary supplements. However, it is not common for clinicians to use CAM as a general therapy in Japan because of the uncertainty regarding the safety and effects of CAM therapies.

Oxidative stress is a key component in the carcinogenesis process.³ Stimulated by endogenous and exogenous factors, reactive oxygen species (ROS) induce cellular damage.³ Although radiation certainly produces ROS, some anticancer agents such as alkylating agents and platinum and antitumor antibiotics exert cytotoxicity by generating free radicals. Some endogenous antioxidant defense mechanisms, such as superoxide dismutase, glutathione peroxidise, and catalase, can counterbalance oxidative microenvironments. Nonenzymatic exogenous antioxidants such as vitamins, minerals, and polyphenols also have the ability to quench ROS activity.³,⁴ Therefore, antioxidant therapies may alleviate the adverse effects of chemotherapy and/or radiotherapy but may antagonize antitumor effects by reducing oxidative damage. They prevent cellular damage of normal organs and tissues by reacting with oxidizing free radicals.⁵ However, whether antioxidants can antagonize antitumor effects of radiotherapy and some types of chemotherapy remains controversial. It is necessary to clarify whether or not these supplements interact with cancer therapy using radiation and chemotherapy.⁶ It is important to note that their effects on prognosis, such as survival rate

¹Osaka University Graduate School of Medicine, Suita City, Japan
Corresponding Author:
Toshinori Ito, Department of Integrative Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, 565-0871, Japan.
Email: a-yasueda@cam.med.osaka-u.ac.jp

Downloaded from ijt.sagepub.com at PAOLI MEMORIAL HOSPITAL on December 8, 2015
Integrative Cancer Therapies and tumor progression, should be determined and the results disseminated widely. In this study, we reviewed antioxidants as an adjuvant therapy for cancer patients during chemotherapy or radiotherapy. As our end point, we aimed to provide information about their effectiveness and safety for survival, tumor development, and relief of adverse effects during chemotherapy or radiotherapy for patients with cancer.

Materials and Methods

Electronic literature searches were performed, and relevant articles from 1982 to July 1, 2014, were obtained. Published human clinical trials in English that used randomized controlled clinical trial (RCT) designs involving administration of antioxidant supplements to cancer patients during chemotherapy or radiotherapy were selected. Additional articles found in review articles that suited our inclusion criteria were added. The chosen results were evaluated by the authors independently according to the inclusion and exclusion criteria.

Studies that targeted cancer patients undergoing chemotherapy or radiotherapy were included. All cancer types and all chemotherapy or radiotherapy regimen types were included. Studies investigating chemopreventive effects using antioxidant supplements were excluded. Studies in which the antioxidant was administered by injection were excluded. Only oral supplements were included. Foods and Chinese medicine and herbs were excluded because it is unclear what their effective components might be. Names of antioxidants used in searches were researched and are listed in Supplementary Figure 1 (available at http://ict.sagepub.com/supplemental).

Results

In total, 399 reports received primary screening. Thereafter, duplicated articles and those that met the exclusion criteria were excluded. Finally, 49 reports that met our inclusion criteria were included: 22 vitamin reports (17 chemotherapy, 8 radiotherapy, including 3 duplicates), 12 phytochemicals and related compounds reports (10 chemotherapy, 2 radiotherapy), 2 amino acid and related substances reports (both chemotherapy), and 13 mineral reports (5 chemotherapy, 8 radiotherapy). Detailed descriptions of the search flow are shown in Figure 1. In Tables 1 to 4, for each category, antioxidant effects on mitigation or aggravation of the adverse effects of cancer therapy are indicated in the

![Figure 1](http://ict.sagepub.com/supplemental)

Figure 1. In total, 399 reports were primarily screened. Thereafter, duplicated articles and those that met the exclusion criteria were excluded. Finally, 49 reports that met our inclusion criteria were included: 22 vitamin reports (17 chemotherapy, 8 radiotherapy, including 3 duplicates), 12 phytochemicals and related compounds reports (10 chemotherapy, 2 radiotherapy), 2 amino acid and related substances reports (both chemotherapy), and 13 mineral reports (5 chemotherapy, 8 radiotherapy). Abbreviation: RCT, randomized controlled trial.
<table>
<thead>
<tr>
<th>No.</th>
<th>Reference</th>
<th>Design</th>
<th>Cancer</th>
<th>Participants (n)</th>
<th>Antioxidants</th>
<th>Chemotherapy</th>
<th>Radiation</th>
<th>End point</th>
<th>Results (Representative)</th>
<th>Survival/Tumor size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Takimoto et al (1982)</td>
<td>RCT</td>
<td>Lung, breast or thyroid</td>
<td>40</td>
<td>CoQ10</td>
<td>Second day: fluorouracil, doxorubicin, cyclophosphamide (every 3 weeks)</td>
<td>First day: radiation 5 Gy (500 rads; cobalt60)</td>
<td>Prevention of cardiotoxicity</td>
<td>• CTR ↑ in control group</td>
<td>• P &lt; .01 vs CoQ10 group</td>
</tr>
<tr>
<td>2</td>
<td>Akihama et al (1983)</td>
<td>Double-blind and placebo-controlled trial</td>
<td>Acute/myeloid leukemia; malignant lymphoma</td>
<td>19</td>
<td>CoQ10</td>
<td>Doxorubicin; cyclophosphamide; vincristine; prednisolone (6 pulse 21-day interval)</td>
<td>Hair loss; change in liver enzyme</td>
<td>Prevention of cardiotoxicity</td>
<td>• Hair loss, NS</td>
<td>• AST/ALT ↑, P &lt; .01 vs 0 week only in placebo group</td>
</tr>
<tr>
<td>3</td>
<td>Okuma et al (1984)</td>
<td>RCT</td>
<td>Lung, malignant lymphoma or others</td>
<td>80</td>
<td>CoQ10</td>
<td>Chemotherapy with Adriamycin about 34.2 to 48 mg/body</td>
<td>Prevention of cardiotoxicity</td>
<td>• QRS voltage: lower in control group</td>
<td>• P &lt; .01 vs CoQ10 group</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Iarussi et al (1994)</td>
<td>RCT</td>
<td>Acute lymphoblastic leukemia or non-Hodgkin lymphoma</td>
<td>10</td>
<td>CoQ10</td>
<td>Adryblastin 120 mg + daunorubicin 120 mg</td>
<td>Prevention of cardiotoxicity</td>
<td>• Group I: %LVFS ↓, P &lt; .05 vs pretreatment</td>
<td>• Group II: %LVFS ↓, P &lt; .002, %SWT ↓, P &lt; .01 vs pretreatment</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Rusciani et al (2007)</td>
<td>RCT</td>
<td>Melanoma stage I to II</td>
<td>81</td>
<td>CoQ10</td>
<td>γIFNα-2b</td>
<td>Metastases</td>
<td>• Overall survival: P = .006 vs IFN group</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Lesser (2013)</td>
<td>Double-blind and placebo-controlled trial</td>
<td>Breast cancer</td>
<td>236</td>
<td>Coenzyme Q10 + vitamin E</td>
<td>Anthracycline, no anthracline</td>
<td>Fatigue</td>
<td>NS</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Meyskens et al (1995)</td>
<td>RCT</td>
<td>Chronic myelogenous leukemia</td>
<td>153</td>
<td>Vitamin A</td>
<td>Busulfan, 8 mg/m²/d, for 4 days every 4 weeks</td>
<td>Overall survival; progression-free survival</td>
<td>Grade 2 toxicities higher in Vitamin A supplementation group, P = .002</td>
<td>• Overall survival: P = .01</td>
<td>Progression-free survival: P = .023</td>
</tr>
<tr>
<td>8</td>
<td>Dagdemir et al (2004)</td>
<td>RCT</td>
<td>Leukemia and lymphoma</td>
<td>35</td>
<td>Vitamin A</td>
<td>High-dose methotrexate (HDMTX), 3000 or 5000 mg/m² every 24 hours, with leucovorin rescue</td>
<td>Intestinal absorption</td>
<td>Progression-free survival</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Wadleigh (1992)</td>
<td>Double-blind and placebo-controlled trial</td>
<td>Head and neck cancer, esophageal cancer, hepatocellular cancer, and acute myelogenous leukemia</td>
<td>18</td>
<td>Vitamin E</td>
<td>Head and neck, esophageal: 5-FU + cisplatin</td>
<td>Mucosal lesions healing</td>
<td>The number of patients who have complete resolution of lesions higher in vitamin E therapy; P = .025</td>
<td>ND</td>
<td></td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>No.</th>
<th>Reference</th>
<th>Design</th>
<th>Cancer</th>
<th>Participants (n)</th>
<th>Antioxidants</th>
<th>Chemotherapy</th>
<th>Radiation</th>
<th>End point</th>
<th>Results (Representative)</th>
<th>Survival/Tumor size</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>Pace et al (2003)</td>
<td>RCT</td>
<td>Solid malignancies (lung, ovarian, rhinopharynx, urethral, gastric, testicular, esophageal, ethmoidal, and tongue cancer)</td>
<td>46</td>
<td>Vitamin E</td>
<td>Cisplatin cumulative dose &gt;300 mg/m² (administered in combination regimens on the basis of tumor size)</td>
<td>Neuroprotective effect</td>
<td>Neurotoxicity scores, group 1 vs group 2; significantly higher in group 2; P &lt; .01</td>
<td>NS (clinical response)</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Ferreira (2004)</td>
<td>Double-blind and placebo-controlled trial</td>
<td>Cancer of the oral cavity and oropharynx</td>
<td>54</td>
<td>Vitamin E (oral rinse)</td>
<td>2 Gy/section (Co60 unit), up to a cumulative dose of 44 Gy/4.5 weeks</td>
<td>Mucositis incidence and symptoms</td>
<td>Incidence density, P = .038</td>
<td>Questionnaire, P = .0001</td>
<td>NS between groups</td>
</tr>
<tr>
<td>12</td>
<td>Argyriou et al (2006)</td>
<td>RCT</td>
<td>Solid or nonmyeloid malignancies (lung, breast, and ovarian cancer)</td>
<td>32</td>
<td>Vitamin E</td>
<td>Paclitaxel based (6 courses)</td>
<td>Efficacy and safety</td>
<td>Incidence PIPN significantly lower in group 1, P = .03</td>
<td>Adverse event, NS</td>
<td>No statistical data</td>
</tr>
<tr>
<td>13</td>
<td>Argyriou et al (2006)</td>
<td>RCT</td>
<td>Solid or nonmyeloid malignancies (lung, testicular, cervix, gastric, and head-and-neck cancer)</td>
<td>30</td>
<td>Vitamin E</td>
<td>Lung: cisplatin + etoposide + irinotecan Testicular: cisplatin + etoposide + ifosfamide Gastric: cisplatin + docetaxel Head and neck: cisplatin + 5-FU</td>
<td>Efficacy and safety</td>
<td>Incidence of neurotoxicity significantly higher in group 2, P = .026</td>
<td>No statistical data</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Chitra and Shyamala Devi (2008)</td>
<td>RCT</td>
<td>Oral cavity cancer</td>
<td>89</td>
<td>Vitamin E</td>
<td>Televcobalt beam ≥6000 cGy Salivary flow rate and the level of each component</td>
<td>Salivary flow rate, P &lt; .001 2s vs 3a, P &lt; 2b vs 3b</td>
<td>Potassium level, P &lt; .01 2s vs 3a, P &lt; .001 2b vs 3b</td>
<td>Ph, P &lt; .01 2s vs 3a, P &lt; .001 2b vs 3b</td>
<td>Activity of amylase, P &lt; .01 3a vs 3b</td>
</tr>
</tbody>
</table>

(continued)
Table 1. (continued)

<table>
<thead>
<tr>
<th>No.</th>
<th>Reference</th>
<th>Design</th>
<th>Cancer</th>
<th>Participants (n)</th>
<th>Antioxidants</th>
<th>Chemotherapy</th>
<th>Radiation</th>
<th>End point</th>
<th>Results (Representative)</th>
<th>Survival/Tumor size</th>
</tr>
</thead>
<tbody>
<tr>
<td>15</td>
<td>Pace et al (2010)</td>
<td>Double-blind and placebo-controlled trial</td>
<td>Cancer patients receiving cisplatin-based chemotherapy</td>
<td>41</td>
<td>Vitamin E</td>
<td>Cisplatin (cumulative dose &gt; 300 mg/m²)</td>
<td></td>
<td></td>
<td>Evaluate the neuroprotective effect</td>
<td>ND</td>
</tr>
<tr>
<td>16</td>
<td>Kottschade et al (2011)</td>
<td>Double-blind and placebo-controlled trial</td>
<td>Cancer patients receiving either taxanes or platinum-based chemotherapy</td>
<td>189</td>
<td>Vitamin E (d-α-tocopherol)</td>
<td>Taxane, cisplatin, carboplatin, and/or oxaliplatin</td>
<td></td>
<td></td>
<td>Prevention effects of peripheral neuropathy</td>
<td>NS</td>
</tr>
<tr>
<td>17</td>
<td>Halperin et al (1993)</td>
<td>Double-blind and placebo-controlled trial</td>
<td>Primary or metastatic brain tumors</td>
<td>65</td>
<td>Vitamin C (l-ascorbic acid)</td>
<td></td>
<td>14 to 70.3 Gy</td>
<td>Skin reaction</td>
<td>NS</td>
<td>ND</td>
</tr>
<tr>
<td>18</td>
<td>Bairati et al (2005)</td>
<td>Double-blind and placebo-controlled trial</td>
<td>Squamous cell carcinoma of the head and neck area (stage I to II)</td>
<td>540</td>
<td>α-Tocopherol + β-carotene</td>
<td></td>
<td></td>
<td>Adverse effect, symptoms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>Pathak et al (2005)</td>
<td>RCT</td>
<td>Non-small-cell lung cancer (stage IIb to IV)</td>
<td>136</td>
<td>Ascorbic acid + α-tocopherol + β-carotene</td>
<td>Paclitaxel and carboplatin</td>
<td></td>
<td>Response rate in chemotherapy/survival rate</td>
<td>NS</td>
<td>NS but slightly lower in supplementation group</td>
</tr>
</tbody>
</table>

- Incidence of neurotoxicity significantly lower in group 1, \( P < .01 \)
- Total neuropathy score significantly lower in group 1, \( P < .01 \)
- Adverse event (larynx) of α-tocopherol + β-carotene ↓ during radiotherapy (OR = 0.38; 95% CI = 0.21 to 0.71)
- QLQ-C30: diarrhea and sleep disturbance \( P = .002 \) vs placebo
- Survival rate, ↓ \( P = .12 \)
- Recurrence initial cancer: \( P = .03 \)
- Mortality from all causes: \( P = .02 \)
- Mortality from initial cancer: \( P = .04 \), during radiation therapy cigarette smokers vs nonsmokers
<table>
<thead>
<tr>
<th>No.</th>
<th>Reference</th>
<th>Design</th>
<th>Cancer</th>
<th>Participants (n)</th>
<th>Antioxidants</th>
<th>Chemotherapy</th>
<th>Radiation</th>
<th>End point</th>
<th>Results (Representative)</th>
<th>Survival/Tumor size</th>
</tr>
</thead>
<tbody>
<tr>
<td>21</td>
<td>Fuchs-Tarlovsky et al (2011)</td>
<td>Double-blind and placebo-controlled trial</td>
<td>Cervical cancer (stage Ib1 to IIIb)</td>
<td>103</td>
<td>β-Carotene + vitamin C + vitamin E + selenium</td>
<td>Cisplatin</td>
<td>Radiation + cisplatin or radiation only, 50 Gy</td>
<td>QOL</td>
<td>• Carbonylated protein ↓, P = .003 vs placebo</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• QOL, P &lt; .025 vs placebo</td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>Suhail et al (2012)</td>
<td>RCT</td>
<td>Breast carcinoma (stage II)</td>
<td>80</td>
<td>Vitamin C, E</td>
<td>5-FU 500 mg/m², Doxorubicin 50 mg/m², Cyclophosphamide 500 mg/m² Every 3 weeks for 6 cycles</td>
<td>Antioxidant enzymes, DNA damage</td>
<td></td>
<td>• MDA ↓, P &lt; .01 vs chemotherapy alone</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• GSH ↑, P &lt; .01 vs chemotherapy alone</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• SOD ↑, P &lt; .01 vs chemotherapy alone</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• CAT ↑, P &lt; .01 vs chemotherapy alone</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• GST ↑</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• P &lt; .01 vs chemotherapy alone</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• GR ↑, P &lt; .01 vs chemotherapy alone</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• DNA damage ↓, P &lt; .01 vs chemotherapy alone</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CI, confidence interval; CTR, cardiothoracic ratio; IFN, interferon; NS, not significantly different between groups; OR, odds ratio; PIPN, peripheral neuropathy; RCT, randomized controlled clinical trial; LVFS, left ventricular fractional shortening; SWT, septal wall thickness; FU, fluorouracil; MDA, malondialdehyde; GSH, reduced glutathione; SOD, superoxide dismutase; QOL, quality of life; QLQ, quality of life questionnaire C30; CAT, catalase; GST, glutathione-S-transferase; GR, glutathione reductase; ND, no data.

*Table indicates the details of each RCT: design, cancer, participants, antioxidants, chemotherapy, radiation, end point, and results (survival/tumor size).
<table>
<thead>
<tr>
<th>No.</th>
<th>Reference</th>
<th>Design</th>
<th>Cancer</th>
<th>Participants (n)</th>
<th>Antioxidants</th>
<th>Chemotherapy</th>
<th>Radiation</th>
<th>End point</th>
<th>Results (Representative)</th>
<th>Survival/tumor size</th>
</tr>
</thead>
<tbody>
<tr>
<td>23</td>
<td>Lissoni, P. (1997)</td>
<td>RCT</td>
<td>metastatic solid tumor (lung cancer, breast cancer and gastrointestinal tract)</td>
<td>80</td>
<td>melatonin</td>
<td>Lung: cisplatin + etoposide&lt;br&gt;Breast: mitoxantrone&lt;br&gt;Gastro: 5-FU + folate</td>
<td>toxicities of chemotherapy</td>
<td>toxicities of chemo vs. chemo + melatonin&lt;br&gt;myelosuppression ( p = 0.006 )&lt;br&gt;asthaenia ( p = 0.0006 )</td>
<td>tumor regression: N.S but tends to be higher in melatonin group&lt;br&gt;survival (1 year): higher in melatonin group vs. control ( p &lt; 0.05 )&lt;br&gt;survival rate: ( p &lt; 0.05 )&lt;br&gt;tumor regression: N.S but tends to be higher in melatonin group</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>Lissoni, P. (1997)</td>
<td>RCT</td>
<td>consecutive NSCLC patients who were unable to tolerate the most aggressive polychemotherapies with high dose cisplatin, anthracyclines, taxol, taxotere and genicitabine</td>
<td>70</td>
<td>melatonin</td>
<td>doxorubicin&lt;br&gt;cyclophosphamide&lt;br&gt;vincristine&lt;br&gt;prednisolone (6 pulse 21-day interval)</td>
<td>• toxicities of chemotherapy&lt;br&gt;• survival rate&lt;br&gt;• clinical response</td>
<td>toxicities of chemo vs. chemo + melatonin&lt;br&gt;myelosuppression ( p &lt; 0.05 )&lt;br&gt;neuropathy ( p &lt; 0.05 )&lt;br&gt;asthaenia ( p &lt; 0.01 )&lt;br&gt;10% of weight loss ( p &lt; 0.001 )</td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>Ghielmini, M. (1999)</td>
<td>Double-blind and placebo controlled trial</td>
<td>NSCLC or small-cell lung cancer (not amenable to surgery or radiotherapy/no previous chemo and radiotherapy)</td>
<td>20</td>
<td>melatonin</td>
<td>carboplatin&lt;br&gt;etoposide</td>
<td>haematological toxicity</td>
<td>N.S</td>
<td></td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>Lissoni, P. (2003)</td>
<td>RCT</td>
<td>consecutive untreated metastatic NSCLC</td>
<td>100</td>
<td>melatonin</td>
<td>cisplatin 20 mg/m^2/ day&lt;br&gt;etoposide 100 mg/m/day</td>
<td>• toxicities of chemotherapy&lt;br&gt;• survival rate&lt;br&gt;• clinical response</td>
<td>toxicities of melatonin (vs. chemo alone)&lt;br&gt;neurotoxicity ( p &lt; 0.01 )&lt;br&gt;thrombocytopenia ( p &lt; 0.01 )&lt;br&gt;weight loss prevention ( p &lt; 0.001 )&lt;br&gt;asthaenia ( p &lt; 0.005 )</td>
<td>Survival from Kaplan–Meier method: higher in melatonin group vs. control ( p &lt; 0.001 )&lt;br&gt;tumor regression: higher in melatonin group ( p &lt; 0.05 )&lt;br&gt;Progressive disease: higher in control vs. melatonin group ( p &lt; 0.01 )&lt;br&gt;tumor response: N.S but slightly ↑ in melatonin group vs. control</td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>Cerea, G. (2003)</td>
<td>RCT</td>
<td>metastatic colorectal cancer (previous chemotherapeutic contain 5-FU)</td>
<td>30</td>
<td>melatonin</td>
<td>CPT-11 125 mg/m^2/week</td>
<td>patients achieving disease control toxicity</td>
<td>patients of disease control archive ( \uparrow ) in CPT-11 + melatonin vs. CPT-11 alone ( p &lt; 0.05 )</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>No.</th>
<th>Reference</th>
<th>Design</th>
<th>Cancer</th>
<th>Participants (n)</th>
<th>Antioxidants</th>
<th>Chemotherapy</th>
<th>Radiation</th>
<th>End point</th>
<th>Results (Representative)</th>
<th>Survival/tumor size</th>
</tr>
</thead>
<tbody>
<tr>
<td>28</td>
<td>Lissoni, P. (2007)</td>
<td>RCT</td>
<td>NSCLC</td>
<td>100</td>
<td>melatonin</td>
<td>cisplatin 20 mg/m²/day etoposide 100 mg/m²/day (3 consecutive days every 28 days)</td>
<td></td>
<td>• toxicities of chemotherapy, clinical response</td>
<td>toxities of chemo with melatonin and 5-MTT (vs. chemo alone) neurotoxicity p &lt; 0.01 asthaenia p &lt; 0.01 anorexia p &lt; 0.05</td>
<td>clinical response (complete response): in melatonin p &lt; 0.05</td>
</tr>
<tr>
<td>29</td>
<td>Lissoni, P. (2007)</td>
<td>RCT</td>
<td>consecutive cancer patients (NSCLC, colorectal, gastric)</td>
<td>370</td>
<td>melatonin</td>
<td>depends on tumor histotype cisplatin, etoposide, gemcitabine, oxaliplatin, 5-FU</td>
<td></td>
<td>• toxicities of chemotherapy, survival rate, clinical response</td>
<td>toxities of chemo with melatonin (vs. chemo alone) thrombocytopenia p &lt; 0.01 neurotoxicity p &lt; 0.05 asthaenia p &lt; 0.01</td>
<td>survival curve higher in melatonin group vs. control p &lt; 0.05 clinical response ↑ in melatonin p &lt; 0.01 disease control ↑ in melatonin p &lt; 0.01</td>
</tr>
<tr>
<td>30</td>
<td>Lissoni, P. (1999)</td>
<td>RCT</td>
<td>metastatic solid tumor (lung cancer, breast cancer, gastrointestinal tract neoplasms, head and neck cancers)</td>
<td>250</td>
<td>melatonin</td>
<td>NSCLC: cisplatin, etoposide, gemcitabine breast: doxorubicin, mitoxantrone, paclitaxel gastrointestinal tract: 5-FU + folic acid neck: cisplatin + 5-FU</td>
<td></td>
<td>• toxicities of chemotherapy, clinical response</td>
<td>toxities of CT + MLT (vs. CT) asthaenia p &lt; 0.001 myelosupression p &lt; 0.001 and so on.</td>
<td>survival (1 year) ↑ in melatonin: all p &lt; 0.05 Cisplatin + etoposide (NSCLC): p &lt; 0.001 5-FU + folic (gastro): p &lt; 0.05 doxorubicin (breast): p &lt; 0.05 regression rate melatonin group ↑: Cisplatin + etoposide (NSCLC): p &lt; 0.001 5-FU + folic (gastro): p &lt; 0.05 doxorubicin (breast): p &lt; 0.05 Progression: longer in melatonin group: p &lt; 0.05</td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>No.</th>
<th>Reference</th>
<th>Design</th>
<th>Cancer</th>
<th>Participants (n)</th>
<th>Antioxidants</th>
<th>Chemotherapy</th>
<th>Radiation</th>
<th>End point</th>
<th>Results (Representative)</th>
<th>Survival/tumor size</th>
</tr>
</thead>
<tbody>
<tr>
<td>31</td>
<td>Guo, Y. (2014)</td>
<td>Double-blind and placebo controlled trial</td>
<td>Cancer patients (gastrointestinal, lung, genitourinary, other)</td>
<td>243 (70 completed)</td>
<td>α-lipoic acid</td>
<td>Platinum based regimen (cisplatin, oxaliplatine)</td>
<td>toxicity of neuropathy</td>
<td>ADL pain ameliorating rate</td>
<td>N.S between each group</td>
<td>N.D</td>
</tr>
<tr>
<td>32</td>
<td>Falsaperla, M. (2005)</td>
<td>RCT</td>
<td>hormone refractory prostate cancer</td>
<td>48</td>
<td>ellagic acid (extracted from Punica granatum seeds)</td>
<td>vinorelbine 25 mg/ mg/week × 6 week</td>
<td>estramustine 280 mg thrice daily × 42 days (28-day cycle)</td>
<td>toxicities of group A (vs. group B) neutropaenia</td>
<td>p &lt; 0.05</td>
<td>NS for survival (p = 0.2)</td>
</tr>
<tr>
<td>33</td>
<td>Grotz, KA. (2001)</td>
<td>Double-blind and placebo controlled trial</td>
<td>head and neck cancer</td>
<td>23</td>
<td>coumarin + troxerutin</td>
<td>Total dose 60 Gy</td>
<td>radiation toxicity (salivary glands, mucosa, pharynx, larynx and cutis)</td>
<td>RTOG score: experimental vs. placebo</td>
<td>U3 : p = 0.015</td>
<td>U4 : p = 0.016</td>
</tr>
<tr>
<td>34</td>
<td>Ryan, J.L. (2013)</td>
<td>Double-blind and placebo controlled trial</td>
<td>breast cancer</td>
<td>30</td>
<td>curcumin</td>
<td>42.6 to 50.4 Gy (16 to 33 sessions)</td>
<td>radiation toxicity for skin</td>
<td>Severe of radiation dermatitis p = 0.008</td>
<td>moist desquamation</td>
<td>p = 0.002</td>
</tr>
</tbody>
</table>

Abbreviations: 5-MTT, 5-methoxytryptamine; CPT-11, irinotecan; NS, not significant; NSCLC, non–small-cell lung cancer; RCT, randomized controlled clinical trial; RTOG, Radiation Therapy Oncology Group; 5-FU, 5-fluorouracil; ADL, activities of daily living; ND, no data.

Table indicates the details of each RCT: design, cancer, participants, antioxidants, chemotherapy, radiation, end point, and results (survival/tumor size).
<table>
<thead>
<tr>
<th>No.</th>
<th>Reference</th>
<th>Design</th>
<th>Cancer</th>
<th>Participants (n)</th>
<th>Antioxidants</th>
<th>Chemotherapy</th>
<th>Radiation</th>
<th>End point</th>
<th>Results (Representative)</th>
<th>Survival/tumor size</th>
</tr>
</thead>
<tbody>
<tr>
<td>35</td>
<td>Lin, PC.</td>
<td>Placebo-controlled RCT</td>
<td>stage III colorectal cancer patients with N2 disease</td>
<td>14</td>
<td>N-acetylcysteine</td>
<td>oxaliplatin (85 mg/m²) biweekly 5-FU (425 mg/m²) weekly leucovorin (20 mg/m²)</td>
<td>chemotherapy-induced neurotoxicity</td>
<td>• NCI-CTC at 8 cycles: ( p = 0.038 ) at 12 cycles: ( p = 0.01 ) vs. placebo • Electrophysiologic evaluations N.S between each group</td>
<td>N.D</td>
<td></td>
</tr>
<tr>
<td>36</td>
<td>Heys, SD.</td>
<td>Double-blind and placebo controlled trial</td>
<td>primary breast cancers</td>
<td>96</td>
<td>L-arginine</td>
<td>doxorubicin cyclophosphamide vincristine prednisolone (6 pulse 21-day interval)</td>
<td>clinical and pathological response</td>
<td>pathological response ↑ in L-arginine group (tumors less than 6 cm in initial diameter) ( p = 0.04 ) vs. placebo</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CTC, common toxicity criteria; NCI, National Cancer Institute; RCT, randomized controlled clinical trial.

*Table indicates the details of each RCT: design, cancer, participants, antioxidants, chemotherapy, radiation, end point, and results (survival/tumor size).
<table>
<thead>
<tr>
<th>No.</th>
<th>Reference</th>
<th>Design</th>
<th>Cancer</th>
<th>Participants (n)</th>
<th>Antioxidants</th>
<th>Chemotherapy</th>
<th>Radiation</th>
<th>End point</th>
<th>Results (Representative)</th>
<th>Survival/tumor size</th>
</tr>
</thead>
<tbody>
<tr>
<td>37</td>
<td>Hu, YJ. (1997)</td>
<td>Cross over RCT</td>
<td>cancer (lung, epidermoid carcinoma, adenocarcinoma,SCLC, breast, gastric carcinoma, primary liver cancer, esophagus carcinoma and colon carcinoma)</td>
<td>41</td>
<td>selenium</td>
<td>cisplatin 60 to 80 mg/m²</td>
<td></td>
<td>toxicity suppression effect of cisplatin (bone marrow suppression and nephrotoxicity)</td>
<td>• urine NAG ↓ in supplementation group p &lt; 0.05 (24h) h, &lt;0.01 (48h h) vs. control group</td>
<td>N.D</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• γGT ↓ in supplementation group p &lt; 0.05 (24h h), &lt;0.001 (24h h) vs. control group</td>
<td>• urine AAP ↓ in supplementation group p &lt; 0.01 (24h h), &lt;0.002 (48h h) vs. control group leukopenia ↓ (bone marrow suppression)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• leukopenia ↓ (bone marrow suppression)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>38</td>
<td>Sieja, K. (2004)</td>
<td>Double-blind and placebo controlled trial</td>
<td>ovarian cancer</td>
<td>62</td>
<td>selenium</td>
<td>doxorubicin cyclophosphamide vincristine prednisolone (6 pulse 21-day interval)</td>
<td>side effect</td>
<td>• (change in blood parameters • serum and hair concentration)</td>
<td>nausea (p&lt;0.0000), vomiting (p&lt;0.0000), stomatitis (p=0.029), hair loss (p&lt;0.05), flatulence (p&lt;0.0000), abdominal pain (p&lt;0.02), weakness (p&lt;0.0000), ill-being (p&lt;0.0000), loss of appetite (p&lt;0.0000) ↓ in studied group vs. control group</td>
<td>N.D</td>
</tr>
<tr>
<td>39</td>
<td>Buntzel, J. (2010)</td>
<td>RCT</td>
<td>squamous cell carcinoma of the head and neck region</td>
<td>39</td>
<td>sodium selenite</td>
<td></td>
<td></td>
<td>1.8 to 2.0 Gy (cumulative doses 60 to 72)</td>
<td>Toxicity suppression of radiotherapy</td>
<td>N.D</td>
</tr>
<tr>
<td>40</td>
<td>Muecke, R. (2013)</td>
<td>RCT</td>
<td>cervical and endometrial cancer (after surgical treatment) selenium concentration: less than 84 µg/l</td>
<td>81</td>
<td>selenium</td>
<td></td>
<td></td>
<td>3D conformal radiotherapy (6 to 18 MV linear accelerator)</td>
<td>Toxicity of radiotherapy</td>
<td>N.D</td>
</tr>
<tr>
<td>42</td>
<td>Weijl, NL. (2004)</td>
<td>Double-blind and placebo controlled trial</td>
<td>malignant tumors (testicular cancer, sarcoma, gastrointestinal cancer, urogenital cancer, head and neck cancer, melanoma and so on.)</td>
<td>48</td>
<td>milky beverage</td>
<td>milky beverage include vitamin C and E and selenium ingredients: protein 3.42, carbohydrate 7.92, fat 0.05</td>
<td>tumor response organ N.S</td>
<td>tumor response N.S</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No.</td>
<td>Reference</td>
<td>Design</td>
<td>Cancer</td>
<td>Participants (n)</td>
<td>Antioxidants</td>
<td>Chemotherapy</td>
<td>Radiation</td>
<td>End point</td>
<td>Results (Representative)</td>
<td>Survival/tumor size</td>
</tr>
<tr>
<td>-----</td>
<td>-----------------</td>
<td>---------------------------------------------</td>
<td>-------------------------------------</td>
<td>------------------</td>
<td>--------------</td>
<td>-----------------------</td>
<td>-----------------------------------</td>
<td>-------------------------------------------</td>
<td>--------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>43</td>
<td>Ripamonti, C.</td>
<td>placebo-controlled RCT</td>
<td>head and neck cancer</td>
<td>18</td>
<td>zinc sulphate</td>
<td>external beam</td>
<td>toxicity prevention</td>
<td>N.S</td>
<td>N.D</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(1998)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>radiotherapy (180 to 200 cGy)</td>
<td>effect of radiation therapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(5 to 9 weeks)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>total dose 45 to 70 Gy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>44</td>
<td>Ertekin, MV.</td>
<td>placebo-controlled RCT</td>
<td>head and neck cancer</td>
<td>27</td>
<td>zinc sulphate</td>
<td>2-Gy fraction and 5</td>
<td>prevention of opportunistic</td>
<td>N.D</td>
<td>N.D</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(2003)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>fractions/week (total 4000 to 7000 cGy)</td>
<td>bacterial and fungal infection</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>45</td>
<td>Ertekin, MV.</td>
<td>placebo-controlled RCT</td>
<td>head and neck cancer</td>
<td>27</td>
<td>zinc sulphate</td>
<td>2-Gy fraction and 5</td>
<td>preventive effect of</td>
<td>N.D</td>
<td>N.D</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(2004)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>fractions/week (total 4000 to 7000 cGy)</td>
<td>radiation-induced oropharyngeal mucositis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>antioxidant enzyme activities</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>46</td>
<td>Ertekin, MV.</td>
<td>placebo-controlled RCT</td>
<td>head and neck cancer</td>
<td>27</td>
<td>zinc sulphate</td>
<td>2-Gy fraction and 5</td>
<td>prevention effect for</td>
<td>N.D</td>
<td>N.D</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(2004)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>fractions/week (total 4000 to 7000 cGy)</td>
<td>radiation toxicity of change in taste</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SOD↓ in zinc group p = 0.03 vs. placebo (at first day after radiation)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>47</td>
<td>Halyard, MY.</td>
<td>Double-blind and placebo controlled trial</td>
<td>head and neck cancer</td>
<td>169</td>
<td>zinc</td>
<td>plan to receive ≥2000</td>
<td>prevention effect for</td>
<td>N.D</td>
<td>N.D</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(2007)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>cGy of external</td>
<td>radiation toxicity of change in taste</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>beam radiotherapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>48</td>
<td>Lyckholm, L.</td>
<td>Double-blind and placebo controlled trial</td>
<td>cancer (acute leukaemia, bladder, breast, cervix, colon, lung, melanoma, non Hodgkin's lymphoma, pancreas, prostate, sarcoma)</td>
<td>41</td>
<td>zinc</td>
<td>chemotherapy (carboplatin, docetaxel, 5-FU, gemcitabine, etoposide, paclitaxel, vincristine and so on)</td>
<td>improvement in altered taste and smell</td>
<td>N.S</td>
<td>N.D</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(2012)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>49</td>
<td>Sangthawan, D.</td>
<td>Double-blind and placebo controlled trial</td>
<td>head and neck cancer</td>
<td>144</td>
<td>zinc sulphate</td>
<td>1.8 to 2.0 Gy (total dose 50 to 70 Gy)</td>
<td>benefit of relieving radiation-induced oral mucositis and pharyngitis</td>
<td>N.S</td>
<td>N.D</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CTC, common toxicity criteria version 2a; PTV, planning target volume; RCT, randomized controlled clinical trial; NAG, N-acetyl-β-D-glucosaminidase; γGT, γ-glutamyl transpeptidase; AAP, alanine aminopeptidase; SOD, superoxide dismutase.

*Table indicates the details of each RCT: design, cancer, participants, antioxidants, chemotherapy, radiation, end point, and results (survival/tumor size).
representative results. Similarly, antioxidant interference with or enhancement of survival rate and/or antitumor efficacy of cancer therapy are also indicated in the tables.

**Vitamins**

The antioxidant effect of vitamins suggests that an adequate intake of these micronutrients would contribute to a lower risk of neoplastic diseases. Vitamins have also been used for reducing oxidative stress during chemotherapy and radiotherapy. The vitamins with antioxidant capacity researched in this study were ubiquinone, carotenoids, retinol, tocopherol, ascorbic acid, and folate. Multivitamins and combinations of multiple vitamins were also included. The results and details of clinical studies are summarized in Table 1 and Supplementary Table 1 (available at http://ict.sagepub.com/supplemental).

**Ubiquinone (Vitamin Q).** Ubiquinone, also known as coenzyme Q10 (CoQ10), is a fat-soluble quinone. It has properties similar to those of other vitamins and is essential for the synthesis of adenosine 5'-triphosphate (ATP). It plays an important role in the electron transport chain, functions as an antioxidant, and prevents lipid peroxidation. It is involved in optimal energy production and maintenance within human cells. Adverse effects of CoQ10 may include insomnia, elevated liver enzymes, rash, nausea, epigastric pain, dizziness, photophobia, irritability, headache, and heartburn. Coenzyme Q10 is a lipid-soluble antioxidant that may protect against mitochondrial ROS, is an essential component of the electron transport system, and as a potent intracellular antioxidant, appears to prevent damage to the mitochondria of the heart. CoQ10 deficiency is significantly higher in cancer patients than in healthy populations. CoQ10 is widely promoted for enhancing or modulating the immune system.

We found 5 clinical trials using CoQ10 alone and 1 trial using a combination of CoQ10 and other vitamins. These results indicated some effectiveness of CoQ10 as an adjuvant therapy in cancer treatment. Among 6 trials, 2 reported tumor development and survival rates. Rusciani et al indicated that the administration of γ interferon α-2b (γIFNα-2b) in combination with CoQ10 for 3 years significantly decreased melanoma metastases rates in patients who were followed up for 5 years compared with those in their control group. Although the mechanism by which coenzyme Q10 affected metastasis is not clear, it is unlikely that antioxidant effects interfered with IFN treatments because IFN appears to work through an immunological rather than a free-radical mechanism. CoQ10 also has an effect on the production of ATP required to compensate for the energy loss during chemotherapy. Chemotherapeutic agents could have deleterious effects on mitochondrial respiratory chains by interfering with CoQ10 and leading to calcium overload, causing myocardial cell necrosis. However, CoQ10 supplementation may be effective in protecting myocardial function from chemotherapeutic cardiotoxicity. Takimoto et al and Okuma et al investigated whether CoQ10 supplementation prevents cardiotoxicity during chemotherapy with anthracycline antibiotics. In all 3 studies, it was reported that supplementation was effective in preventing cardiotoxicity caused by anthracycline antibiotics. However, there is some doubt about the evidence quality of these older studies, which have small sample sizes and other study design issues.

These results indicate that CoQ10 may provide some protection against toxicity and deterioration associated with chemotherapy or radiotherapy. No adverse effects caused by CoQ10 supplementation were reported in any trial.

**Retinol (Vitamin A).** Retinoids are reported to inhibit tumor growth on both exocrine and endocrine human pancreatic cell lines. Retinoids and IFNs act synergistically in inhibiting the growth of several cell lines. Furthermore, it is reported that retinol has a protective effect on the mucosa of the gastrointestinal system. However, very few RCTs were performed that combined cancer therapy and retinol supplementation. Regarding tumor development and survival rate, a report on retinol supplementation during cancer therapy was found. However, we excluded this study because it did not meet our inclusion criteria (article in French).

Dagdemir et al reported that high-dose retinol supplementation with methotrexate reduces adverse effects of intestinal malabsorption during chemotherapy in children with leukemia and lymphoma. Although methotrexate is classified as an antimetabolite, it is not reported to increase oxidative stress. On the other hand, Meyskens et al reported that the control group in a vitamin A supplementation study had a significantly increased risk of disease progression and death, although toxicities greater than grade 2 were higher in the vitamin A supplementation group.

**Tocopherol (Vitamin E).** The main constituent of vitamin E is α-tocopherol, a lipid-soluble vitamin. It is the most important natural antioxidant, scavenging ROS and boosting cellular antioxidative capacity to reduce oxidative damage. Radiation-induced oxygen free radicals have been implicated as mediators of radiation-induced mucosal cell injury.

We found 3 clinical trials using α-tocopherol or vitamin E alone and another 6 trials using a combination of β-carotene, ascorbic acid, selenium, and CoQ10. Among these, 6 trials used α-tocopherol in combination with other vitamins. These were included in the “multiple combination with vitamins” category.

Regarding tumor development and survival rates, Ferreira et al conducted a double-blind and placebo-controlled RCT...
and concluded that mouthwashes (used to thoroughly rinse the oral cavity for 5 minutes and then swallowed immediately) containing vitamin E did not affect the survival rate of patients with cancer of the oral cavity and oropharynx. In addition, they reported that the supplementation reduced the incidence of mucosal adverse effects during radiotherapy. They reported no adverse effects caused by vitamin E supplementation. Two groups, Pace et al.\textsuperscript{46} and Kottschade et al.\textsuperscript{47} performed clinical trials using vitamin E for cancer patients treated with taxane or platinum. They reported that no significant difference in peripheral neuropathy was observed between the supplementation group and control group. Argyriou et al.\textsuperscript{48,49} and Pace et al.\textsuperscript{50} reported that vitamin E supplementation significantly protects against chemotherapy (cisplatin/paclitaxel)-induced neurotoxicity. Similarly, Wadleigh et al.\textsuperscript{51} reported that application of vitamin E oil to the oral lesions may be effective for chemotherapy-induced mucositis. Chitra and Shyamala Devi\textsuperscript{52} performed a clinical trial for patients with oral cavity cancer. They concluded that \(\alpha\)-tocopherol supplementation improves the salivary flow rate, thereby maintaining salivary parameters such as pH, activity of amylase, protein, and sodium during radiotherapy. These results suggest that \(\alpha\)-tocopherol supplementation may have a preventive effect against radiation-induced oxygen free-radical toxicity.

**Ascorbic Acid (Vitamin C).** Ascorbic acid, vitamin C, is a water-soluble antioxidant. It is thought to counteract free radicals and prevents organ and tissue damage caused by adverse effects of chemotherapy and radiotherapy.\textsuperscript{53} In this review, there were no reports found on tumor development and survival rates using ascorbic acid during cancer therapy.

Regarding radiotoxicity, Halperin et al.\textsuperscript{64} investigated protective effects of a vitamin C solution on the skin. It was applied to the radiation site before radiotherapy in patients with brain tumors. However, the skin radiotoxicity score and diagnosis results indicated no significant effect. They reported a rusty discoloration on the skin caused by the application of ascorbic acid solution.

**Carotenoid and Multiple Vitamin Combinations.** More than 40 carotenoids have been identified in human blood samples; of these, \(\alpha\)-carotene, \(\beta\)-carotene, lutein, \(\beta\)-cryptoxanthin, lycopene, and zeaxanthin are found at higher levels.\textsuperscript{55} It appears that carotenoids have various chemopreventive actions.\textsuperscript{56} Because of its cancer prevention and regression effects, lycopene has been adopted for use in various cancers types. It is also the most potent quencher of free radicals and is an immunomodulator.\textsuperscript{57,58}

We found 4 trials using carotenoids in combination with other antioxidants. Among them, 3 trials investigated survival rates and reported both positive and negative data. Bairati et al.\textsuperscript{59} indicated that \(\beta\)-carotene treatment in combination with \(\alpha\)-tocopherol has the potential to decrease the occurrence and severity of adverse effects of radiations in patients with squamous cell carcinoma of the head and neck. In contrast, antioxidant vitamins may interfere with treatment efficacy, although this negative aspect was not found to be significant (\(P = .12\)). Although there was no statistical significance, the survival rate of the supplementation group was slightly lower than that of the placebo group. Although the studies of Bairati et al.\textsuperscript{40} and Meyer et al.\textsuperscript{52} were the same trial, we have included both of them because outcome variables presented in each article were different. Meyer et al.\textsuperscript{65} performed a subgroup analysis that verified that \(\alpha\)-tocopherol and \(\beta\)-carotene supplementation had a significant negative effect on cigarette smokers undergoing radiotherapy, particularly with respect to recurrence (\(P = .03\)), all-cause mortality (\(P = .02\)), and initial cancer (\(P = .04\)) of head and neck cancer (HNC). For patients who smoked during radiation therapy compared with those who did not smoke during radiation (not shown in Table 1), they reported high adjusted hazard ratios (HRs) for recurrence (HR = 2.41, smokers; HR = 1.07, nonsmokers), all-cause death (HR = 2.26, smokers; HR = 1.14, nonsmokers), and death from the initial cancer (HR = 3.38, smokers; HR = 1.06, nonsmokers). Furthermore, increased HRs were reported in patients who smoked even prior to and after radiation therapy. On the other hand, Pathak et al.\textsuperscript{66} conducted an RCT for non–small-cell lung cancer (NSCLC) patients and researched the chemotherapy response and survival rate with and without supplementation using multiple antioxidants. They concluded that the data indicated a slightly higher response and survival rate in the supplementation group, but there was no significant difference between groups.

Regarding antioxidant effects of supplementation, a trial with antioxidant supplementation for patients with cervical cancer was performed by Fuchs-Tarlovsky et al.\textsuperscript{45,59} They indicated that \(\beta\)-carotene, vitamin C, vitamin E, and selenium supplementation lowered the level of carbonylated proteins and maintained higher QOL scores in global and cognitive ability (using quality of life 30(QOL-30) and quality of life questionnaire CX24 (QLQ-CX24)) compared with placebo, which may have decreased active oxygen induced by chemotherapy with cisplatin and/or radiotherapy. In addition, using combinations of vitamins, Suhail et al.\textsuperscript{64} performed an RCT for healthy individuals and for breast cancer patients during chemotherapy. They concluded that using vitamin C and E therapy significantly prevented chemotheraphy-induced DNA damage assessed in the peripheral lymphocytes. They did not indicate the survival rate and tumor response.

**Phytochemicals and Related Compounds**

In addition to minerals, amino acids, and vitamins, certain phytochemicals and related compounds have an antioxidant...
capacity. Here, the phytochemicals and related compounds with antioxidant efficacy that we studied included polyphenols, allicin, melatonin, α-lipoic acid, uric acid, urobinogen, ferulic acid, melanoidin, phytic acid, and saponin. The results of the research and the details of the clinical trials are shown in Table 2 and Supplementary Table 1.

Melatonin. Melatonin (5-methoxytryptamine) is a neurohormone secreted from the pineal body. Myeloprotective and immunoenhancing effects of melatonin have been demonstrated in vitro and in vivo experimental models. Melatonin, a potent antioxidant, plays various roles in regulating circadian rhythms, sleep, tumor growth, and ageing. For many years, it has been known that it plays an important anticancer role. As an antioxidant agent, melatonin enhances the prevention of free-radical production and potentially protects against chemotherapy-induced toxicity.

In this study, all the included articles used melatonin combined with chemotherapy. Many of them reported positive data regarding tumor development and survival rates when melatonin was combined with chemotherapy. The survival rate of patients with NSCLC and other cancers was significantly higher with melatonin supplementation when combined with chemotherapy using, for example, cisplatin and etoposide. Similarly, tumor regression rates were significantly higher with melatonin supplementation. The study of Cerea et al. and many other studies reported positive results regarding toxicity reduction and clinical response. However, Ghielmini et al. performed a double-blind and placebo RCT for NSCLC patients whose chemotherapy regimen included cisplatin and etoposide. They reported that there was no significant difference in regard to hematological toxicity in their trial.

In almost all the trials, melatonin supplements were administered in the evening. This was based on the idea that the synthesis of melatonin is strictly controlled by lighting conditions and shows a clear circadian rhythm, with lower levels during the daytime and significantly higher levels at night. There were no severe adverse effects of melatonin supplementation.

α-Lipoic Acid. The administration of α-lipoic acid has been shown to be effective in the treatment of diabetic distal sensorimotor neuropathy. Similarly, the effect of α-lipoic acid on chemotherapy-induced peripheral neuropathy has been investigated. The neuroprotective mechanism of α-lipoic acid is related to the reduction of oxidative stress from free-radical formation. It also has a protective effect during chemotherapy via the regulation of proinflammatory cytokines.

Guo et al. conducted a double-blind, placebo-controlled trial for patients undergoing platinum-based chemotherapy. Although only 28% of patients in the supplementation group and 30% in the placebo group completed this trial, they reported no significant effects in regard to the tumor reduction rate, activities of daily living, or chemotherapy-induced toxicity such as neurotoxicity and pain. No severe adverse effects caused by supplementation were found. This was the only RCT using α-lipoic acid; therefore, further RCTs using α-lipoic acid are required.

Polyphenols. Polyphenols compounds have been widely studied for their antioxidant properties. They are found in many foods such as chocolate, tea, red wine, and pomegranate juice, which are an integral part of the human diet. The polyphenols researched in this study were ellagic acid, coumarin, curcumin, catechin, resveratrol, anthocyanidin, tannin, rutin, isoflavone, quercetin, chlorogenic acid, and lignan.

Ellagic acid. Ellagic acid is an antioxidant substance that can be found in certain plants. It is an effective anti-mutagen and anticarcinogen phytotherapeutic agent that prevents carcinogens from binding to DNA. It may keep cancer cells from spreading and inhibits cancer onset and tumor proliferation during radiotherapy and chemotherapy in laboratory studies.

Falsaperla et al. conducted RCT using ellagic acid during chemotherapy for patients with hormone-refractory prostate cancer. They investigated clinical responses and survival rates. They indicated that the administration of alkaloid antitumor agents in combination with ellagic acid did not significantly affect the survival rate. However, ellagic acid supplementation significantly reduced chemotherapy neutropenia. A trend in serum prostate specific antigen reduction (>75%) was observed in the supplementation group, but there was no significant difference between each group. No significant adverse effects caused by ellagic acid supplementation were found. It is possible that ellagic acid reduces the effect of chemotherapy-induced toxicities; however, further studies are required.

Coumarin. Coumarins are benzopyrones that have antioxidant and anti-inflammatory effects. It is suggested that antioxidants exert their protective effect against cancer by inhibiting the formation of carcinogenic metabolites. However, some studies have reported that coumarin supplements cause liver toxicity. In this study, we found 1 RCT using coumarin supplementation, which did not present results about the survival rate or clinical response.

Grotz et al. performed a double-blind and placebo RCT and reported that the combination of coumarin and troxerutin supplementation reduced the toxicity of radiation in patients with HNC. They reported no severe adverse effects caused by coumarin supplementation. However, there was only a single RCT using coumarin, and further RCTs are required to determine its safety and efficacy as a supplement.

Curcumin. Curcumin, a polyphenol contained in turmeric, has potent antioxidant, anticancer, and anti-inflammatory effects. Some clinical trials have revealed that curcumin...
lowered the toxicity of pancreatic cancer treatment, although diarrhea was an adverse effect in some.\(^8^8\)

In this study, we found 1 RCT using curcumin supplementation, with no results concerning the survival rate or clinical response. Ryan et al\(^8^7\) performed a double-blind and placebo-controlled RCT for breast cancer patients. They reported that curcumin relieved radiation skin toxicities, without causing any severe adverse effects. Other trials\(^8^8\text{-}^9^0\) were not categorized as RCTs.

**Amino Acids and Related Substances**

Recently, the antioxidant efficacy of certain amino acids and related substances—namely glutathione, N-acetylcysteine, methionine, albumin, lactoferrin, and arginine—has attracted attention. The results of the research and trial details are shown in Table 3 and Supplementary Table 1.

**N-Acetylcysteine.** N-Acetylcysteine supplementation can increase whole blood concentrations of glutathione, which is a tripeptide associated with reduced chemotherapy-induced neurotoxicity.\(^9^2\) N-acetylcysteine has not been as well studied as other amino acids. Lin et al\(^9^2\) performed a placebo-controlled RCT for colorectal cancer patients. They did not indicate the results of survival rates or clinical response. They investigated the efficacy of reducing chemotherapy-induced toxicity. Their results showed that N-acetylcysteine significantly reduced chemotherapy-induced neurotoxicity. They reported no severe adverse effects caused by N-acetylcysteine supplementation. However, there was only 1 RCT using N-acetylcysteine, and further RCTs are required to determine its safety and efficacy as a supplement.

**L-Arginine.** L-Arginine is the biological precursor of endogenous nitric oxide, which is a potent vasodilator and key for immunological functions.\(^9^3\) It also regulates antioxidant-related signaling molecule expression.\(^9^4\)

Heys et al\(^9^5\) conducted a double-blind, placebo-controlled RCT for patients with primary breast cancer. They indicated that L-arginine supplementation significantly increased the pathological response to chemotherapy using doxorubicin, cyclophosphamide, vincristine, and prednisolone in the supplementation group. However, they did not investigate survival rates or clinical response data. They reported no severe adverse effects caused by L-arginine supplementation. However, there was only 1 RCT using L-arginine, and further RCTs are required to determine its safety and efficacy as a supplement.

**Minerals**

Some minerals chelate substances, thereby exerting an antioxidant effect. These minerals were reported to be susceptible to oxidation-reduction reactions.\(^7\text{-}^9^4\text{,}^9^6\text{-}^9^8\) In this study, chromium, transferrin (ferritin), selenium, manganese, molybdenum, and zinc met our inclusion criteria. The results of the research and trial details are shown in Table 4 and Supplementary Table 1.

**Selenium.** Selenium has been shown to possess cancer-preventive and cytoprotective qualities.\(^1^0^0\) It affects a wide range of biological processes, including energy metabolism and membrane integrity (by acting as an antioxidant), as well as protecting against DNA damage, exerting anti-inflammatory effects, and regulating the production of active thyroid hormone.\(^1^0^0\text{-}^1^0^1\)

Based on these capabilities, some clinical trials were performed with cancer patients during chemotherapy or radiotherapy. We found 6 results (4 chemotherapy, 2 radiotherapy) for selenium use during cancer therapy. No significant adverse effects of selenium supplementation were found. None of the selected trials reported survival rates or clinical response data, but a follow-up study assessed survival 6 years after 1 trial.\(^1^0^1\text{-}^1^0^2\) The study reported that there was no significant difference in 6-year survival between groups.\(^1^0^2\)

Buntzel et al\(^1^0^3\) and Muecke et al\(^1^0^4\) performed RCTs for patients undergoing radiotherapy for HNC, and cervical and endometrial cancer. They concluded that selenium supplements reduced the number of episodes and the severity of radiotoxicities, such as dysphagia and diarrhea.

Hu et al\(^1^0^4\) and Sieja and Talerczyk\(^1^0^5\) performed RCTs using placebo controls for patients with many cancer types undergoing chemotherapy using cisplatin. They concluded that selenium supplements reduced the nephrotoxicity and neurotoxicity of cisplatin. Elsendoorn et al\(^1^0^6\) and Weijl et al\(^1^0^7\) conducted a double-blind and placebo RCT for patients with many cancer types undergoing chemotherapy with cisplatin. They used a combined supplement of selenium, vitamin C, and vitamin E. In contrast to the result of Hu et al\(^1^0^4\) and Sieja and Talerczyk,\(^1^0^5\) they found no significant difference between trial groups regarding chemotherapy-induced organ toxicity.

**Zinc.** Zinc, a major dietary antioxidant, protects the airway epithelium against oxyradicals and other noxious substances. Zinc, therefore, has important implications for asthma and other inflammatory diseases, where the physical barrier is vulnerable and compromised.\(^1^0^8\) Some studies used zinc supplements to study its effect on maintaining and priming the immune system and tissue repair. There were 7 RCTs in this study, none of which provided data regarding survival rates or clinical responses. Most of them reported no severe adverse effects caused by zinc supplementation.

Sangthawan et al\(^1^0^9\) and Ripamonti et al\(^1^1^0\) performed RCTs using placebo controls for patients undergoing radiotherapy for HNC. They concluded that compared with placebo controls, zinc supplementation was not significantly effective in relieving radiotoxicities such as taste alterations, weight loss, nausea, and vomiting.
Similarly, Lyckholm et al\textsuperscript{111} found that zinc supplementation did not significantly improve chemotoxicity in terms of altered taste and smell. In addition, Ertekin et al\textsuperscript{112-114} and Halyard et al\textsuperscript{15} conducted an RCT for patients undergoing radiotherapy for HNC. They reported that zinc supplementation was effective in preventing opportunistic bacterial infections and radiotherapy-induced oropharyngeal mucositis and promoting antioxidant enzyme activities. Although the 3 articles of Ertekin et al\textsuperscript{112-114} reported on the same trial, we included all of them because the outcome variables presented in each article were different.

Discussion

Survival/Clinical Response

In 17 articles\textsuperscript{23,36,40-42,45,46,63-69,79,95,107} of 49 (approximately 35%) included in this study, effects on patient survival or clinical response during chemotherapy and/or radiotherapy were described. In 7 of 17 RCTs using melatonin supplementation, 4 reported a significantly increased survival rate and 4 reported a significantly increased the tumor regression rate. In addition, 1 trial each using vitamin A\textsuperscript{46} and multiple vitamins\textsuperscript{42} reported a significantly increased survival rate. On the other hand, 2 trials using multiple vitamins\textsuperscript{40,41} reported that there were no significant differences between supplementation and control groups, although the survival rates of the supplementation groups were slightly lower than those of the control groups. Two trials using vitamin E\textsuperscript{55,46} reported that there was no significant difference in clinical response between groups. Also, the RCT using ellagic acid reported that there were no significant differences between groups in survival rate and clinical response.\textsuperscript{79} Similarly, a trial using \(\ell\)-arginine supplementation reported a significant increase in the pathological response.\textsuperscript{95} On the other hand, a trial using combination supplement (vitamins C and E and selenium)\textsuperscript{107} reported that there was no significant difference in clinical response. In addition to our 49 results, Muecke et al\textsuperscript{102} performed a follow-up study of their 2013 report.\textsuperscript{101} They reported that there were no differences between groups in 6-year survival rate using selenium supplementation during radiation.

We list anticancer agents by class and whether they produce ROS in Supplementary Table 2 (available at http://ict.sagepub.com/supplemental).\textsuperscript{116} From the results of this review, there might be a possibility that potent antioxidant supplementation could reduce therapeutic effects of radiotherapy or chemotherapy using alkylating agents, platinum compounds, or anthracycline. These agents exert a therapeutic effect by generating active oxygen. Compared with regular doses (6-8 mg/d) as sleep aid, high-dose melatonin supplementation (20-40 mg/d dose) was administered in all trials in this review. In the case of melatonin and also for vitamin C, higher dose or stronger antioxidants might protect not only normal cells from ROS-generating therapies, but might also protect cancer cells themselves by helping them proliferate. On the other hand, it is also known that a higher dose of antioxidant can function as a pro-oxidant in cancer cells\textsuperscript{99,117} suggesting that high-dose antioxidants might augment effects of ROS-generating therapies. Lower-dose antioxidant supplementation may protect normal cells and reduce the toxicity of radiation and chemotherapy.\textsuperscript{42} However, it is difficult to demonstrate either positive or negative effects of antioxidant supplementation on patient survival and growth inhibition of cancer cells in the studies reviewed in this article.

However, a negative effect was demonstrated by Meyer et al\textsuperscript{42} studying HNC patients who were undergoing radiotherapy and who also smoked. Their data indicated that \(\alpha\)-tocopherol and \(\beta\)-carotene supplementation with radiotherapy significantly increased recurrence and mortality in patients who smoked during radiation therapy, although not in nonsmoking patients. In evaluating the negative results of that study, 2 factors were suggested to interact with each other. The first was that antioxidant supplementation scavenged free radicals and reduced the damage caused by ionizing radiations. The second was that the carbon monoxide scavenged free radicals and reduced the damage caused by ionizing radiations. It is known that carbon monoxide has 200 to 300 times higher affinity for hemoglobin than oxygen. It is difficult to generate ROS in a state of oxygen deficiency. Furthermore, cancer cells can adapt to hypoxia\textsuperscript{119} which results in invasion, metastasis, and angiogenesis.\textsuperscript{120} Cancer cells stop growing during hypoxic cell cycle arrest, making any treatment less effective. It is, therefore, suggested that a combination of smoking with the consumption of a strong antioxidant during radiotherapy may create a favorable condition for cancer growth, resulting in lower survival rates.

Reduction of Adverse Effects: Chemotherapy

Among the 49 studies, 46 examined the reduction of adverse effects by antioxidant supplementation. In 34 trials, possible reductions in chemotoxicities or radiotoxicities using antioxidant supplementation were reported. On the other hand, only 1 RCT, using vitamin A, reported that supplementation possibly increased chemoinduced toxicities. The remaining 11 studies displayed no difference in toxicities between control and supplementation groups.

Chemotherapy and radiotherapy cause various adverse effects, which may in part be caused by free radicals and ROS.\textsuperscript{121} ROS generation causes various tissue or organ injuries\textsuperscript{122}: doxorubicin and other anthracycline antibiotics are known to lead to cardiotoxicity\textsuperscript{123}; cisplatin and other platinums lead to nephrotoxicity, ototoxicity, and peripheral neuropathy\textsuperscript{124,125}, bleomycin leads to lung injury\textsuperscript{126}, and alkylating agents cause DNA damage of drug-treated cells.\textsuperscript{8,127} Carcinogenesis may also occur as the result of tissue or organ injuries.\textsuperscript{122}
In 18 RCTs in which platinum was used as the therapeutic agent, the effects of melatonin, selenium, and vitamin supplementation on chemotoxicities were reported. Among 7 trials using melatonin, 6 reported that melatonin supplementation significantly improved myelosuppression, weight loss, and neurotoxicity. Selenium supplementation was used in 4 trials. In 2 trials selenium supplementation was reported to be significantly effective for nephrotoxicity and QOL. Vitamins were used in 7 RCTs, showing a significant improvement of QOL in 1 trial and a significant decrease of various chemoinduced toxicities in 5 trials. Similarly, we found 7 RCTs studying the effects of melatonin or vitamin E on relieving toxicities of plant alkaloid–based chemotherapy, although these regimens were not considered to exert cytotoxicity by generating free radicals. All of them reported that melatonin or vitamin E supplementation was significantly effective in reducing toxicities. Furthermore, we found 5 studies that researched the interaction between antioxidants and alkylating chemotherapy (cyclophosphamide). In 3 trials of 5 using cyclophosphamide regimens, there was a significant effect of antioxidants on chemoinduced toxicity. One trial using busulfan reported improvement in chemoinduced toxicities for more patients in the thalidomide supplementation group than in controls.

As described above, a significant relief in chemotherapy-induced toxicities was reported in many trials using various antioxidant supplements. However, among trials in which the same combination of chemotherapeutic agent and antioxidant was used, some reported effective outcomes, whereas others did not. This could be considered to be dependent on the dosage and/or patient’s background rather than on a scale difference of the trials.

Reduction of Adverse Effects: Radiation

In total, 19 radiotoxicity prevention trials were investigated, which specifically aimed to reduce toxicities affecting the mucosa, skin, salivary glands, and taste. Four of 19 trials reported no significant differences in toxicity between groups. Antioxidant supplements such as vitamin E, multivitamin combination, polyphenol, and zinc were effective in preventing radiation-induced toxicities in the skin, mucosa, and salivary glands.

Clinical Use of Antioxidant Supplements

Regarding the conflicting issues related to antioxidant use in cancer chemotherapy or radiotherapy, although a large, well-designed review of the relationship between mitigating effects of antioxidants and oxidative stress caused by anticancer agents is warranted, various aspects of the relationship between cancer and antioxidants have already been investigated. Using animal and in vitro experiments, Chandel and Tuveson demonstrated that antioxidants do not prevent cancer and may accelerate tumor development by targeting ROS in the cell. They caution that antioxidant supplementation should be carefully utilized in cancer patients undergoing concurrent cancer therapy. It may be highly arguable whether cancer patients during cancer therapy should freely use antioxidants.

Finally, the efficacy of each combination of anticancer agent with antioxidant supplement requires adequate verification. In the present research, there were no investigations in which the study drug proliferated the growth of cancer and increased mortality. However, if we want to use antioxidant supplements as CAM for cancer patients, further investigations are required for each and every combination of cancer, dietary supplement, and therapy. Unsupervised use of supplements should be avoided.

One limitation of our review is that we included some trials with low Jadad scores. In most systematic reviews, trials scoring more than 3 are included. In our selected 49 studies, there were 23 trials that scored more than 3. However, we felt that Jadad scores themselves had limitations in describing study quality. Some studies met our inclusion criteria even though they had low Jadad scores. We have, therefore, included all studies but described them in detail in Tables 1 to 4 to allow the reader to judge study quality. With regard to statistical data integration, it is difficult to perform a meta-analysis with this set of studies because of variability of the data available for each antioxidant. Thus, data were compiled without statistical analysis.

To examine the viability and safety of antioxidants in pathological conditions and cancer therapy, trials should be performed with a single regimen, single type of cancer, and single antioxidant. Only such investigations would adequately describe the safety and effectiveness of antioxidant use by cancer patients during therapy. However, in our research, only 2 trials that met those conditions reported survival rate or tumor development. Similarly, only 5 trials that met those conditions reported effects on chemoinductions or radiotoxicities. Therefore, we are unable to judge the effectiveness and safety of antioxidants definitively.

In conclusion, it was difficult to determine whether antioxidants may have an impact on treatment outcomes or whether they may ameliorate adverse effects of chemotherapy and radiotherapy. Discussion of antioxidant use has sometimes distinguished palliative versus curative regimens. For curative regimens, it is important not to inhibit therapy in any way, and patients are usually in better overall condition to tolerate side effects. In palliative or recurrent settings, however, patients are less able to tolerate side effects, and cytotoxic efficacy may be less of a concern than maintaining the patient in treatment. Basically, stable disease is acceptable in this situation if side effects can be managed. Thus, it is important that clinicians make an integrated decision, taking into account the following: (1) the antioxidant dosage and types, (2) the background and state of the patient, and (3) type of cancer and antitumor therapy. It is
desirable to use an evidence-based method to select supplements best suited to cancer patients. Although there are many opinions about the risks or benefits of antioxidant supplementation, the only supportable conclusions based on the present research are that it is difficult to demonstrate definitively that antioxidants ameliorate therapeutic toxicities and that there is no evidence of antioxidant supplementation causing harm alongside cancer therapy, except for smokers undergoing radiotherapy.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

References


78. Smith WA, Gupta RC. Determining efficacy of cancer chemopreventive agents using a cell-free system concomitant with DNA adduction. Mutat Res. 1999;425:143-152.


